Pharma channel feed

Af­ter crit­ics lam­bast­ed Gilead for grab­bing the FDA's spe­cial rare drug sta­tus on remde­sivir, they're giv­ing it back

6 years ago
FDA+
Coronavirus

Bay­er fires em­ploy­ee who was spot­ted break­ing quar­an­tine in Chi­na

6 years ago
China
Coronavirus

An­oth­er an­tibi­ot­ic mak­er bites the dust, as Tetraphase is swal­lowed for cheap

6 years ago
Deals

Intar­ci­a's speed bump at the FDA turns in­to a road­block, as reg­u­la­tors once again turn thumbs down on di­a­betes drug/de­vice

6 years ago
R&D

Bris­tol My­ers backs a Eu­ro­pean VC's record-set­ting biotech ven­ture fund, which tops out at $600M

6 years ago
R&D

Nine new coro­n­avirus cas­es are tied to the Bio­gen out­break — as in­fec­tions spread to 'close con­tact­s'

6 years ago
People
Coronavirus

FDA ap­proves ex-No­var­tis drug for Cush­ing’s dis­ease

6 years ago

As Bio­gen grap­ples with coro­n­avirus cri­sis, Big Phar­mas like Eli Lil­ly, Take­da hun­ker down, tell staffers to work from home

6 years ago
Coronavirus

Eu­ro­pean reg­u­la­tors ex­pand use of Ab­b­Vie's two-month hep C reg­i­men

6 years ago

As­traZeneca's Imfinzi fails blad­der can­cer tri­al — in pa­tient pop­u­la­tion cov­ered by FDA's 2017 ac­cel­er­at­ed ap­proval

6 years ago
R&D

More than half of its gross sales ul­ti­mate­ly went to pay­ers as re­bates, Sanofi says

6 years ago

FDA re­quires boxed warn­ing for Sin­gu­lair and its gener­ics

6 years ago
FDA+

Vil­i­fied for high drug prices, what does the prof­itabil­i­ty of ma­jor US phar­ma com­pa­nies look like?

6 years ago

AM­AG CMO hits the ex­it just as biotech search­es for new CEO to right a ship rocked by Mak­e­na con­tro­ver­sy

6 years ago
People

Add Take­da and Al­ny­lam to the menu of glob­al drug­mak­ers look­ing to stymie the coro­n­avirus epi­dem­ic

6 years ago
R&D
Coronavirus

As costs con­tin­ue to soar ever high­er, As­traZeneca sees new HQ stick­er price gy­rate to $1.28B

6 years ago

Karyopharm spot­lights PhI­II re­sults af­ter con­tro­ver­sial FDA ap­proval

6 years ago
R&D

The FDA OKs gener­ic Dara­prim, the Mar­tin Shkre­li ther­a­py that trig­gered an un­end­ing tem­pest over drug pric­ing

6 years ago

Why FDA can’t dis­close the first coro­n­avirus-re­lat­ed drug short­age

6 years ago
FDA+
Coronavirus

Bio­haven scores CGRP OK for acute mi­graine — can the com­mer­cial team catch up with Al­ler­gan on its de­but?

6 years ago

Mallinck­rodt, once the na­tion’s largest oxy­codone pro­duc­er, an­nounces ten­ta­tive $1.6B set­tle­ment

6 years ago
Deals

No­var­tis' plans to wres­tle Eylea mar­ket share take a hit as Beovu is linked to safe­ty con­cerns

6 years ago
FDA+

Sanofi out­lines big API plans as coro­n­avirus out­break re­port­ed­ly threat­ens short­age of 150 drugs

6 years ago
China

The fourth CGRP mi­graine drug is here. Time for Lund­beck to prove it's worth $2B

6 years ago
FDA+
First page Previous page 255256257258259260261 Next page Last page
A service from the Financial Times